Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents: Implications for cholinergic involvement in Parkinsonism

Life Sciences

Volumn 68, Issue 22-23, 2001, Pages 2579-2584

  Salamone, John D ^a   Correa, Merce ^a   Carlson, Brian B ^a   Wisniecki, Anna ^a   Mayorga, Arthur J ^a   Nisenbaum, Eric ^b   Nisenbaum, Laura ^b   Felder, Christian ^b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

Acetylcholine; Basal ganglia; Motor; Parkinson; Tremor

Indexed keywords

3 ALLYL 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; AMANTADINE; ANTIPARKINSON AGENT; APOMORPHINE; BENZATROPINE; BROMOCRIPTINE; CHOLINERGIC RECEPTOR STIMULATING AGENT; CLOZAPINE; DIPHENHYDRAMINE; LEVODOPA; METHOCTRAMINE; MUSCARINIC M4 RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PERGOLIDE; PILOCARPINE; PIRENZEPINE; ROPINIROLE; SCOPOLAMINE; SKF 38389; TELENZEPINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLINERGIC SYSTEM; CONTROLLED STUDY; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; JAW MOVEMENT; KNOCKOUT MOUSE; LOCOMOTION; MOUSE; NEOSTRIATUM; NONHUMAN; PARKINSONISM; RAT; RECEPTOR BLOCKING; TREMOR;

PARKINSONIA; RODENTIA;

EID: 0035957582     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0024-3205(01)01055-4     Document Type: Conference Paper

References (25)

1. Duvoisin R Cholinergic-dopaminergic antagonism in parkinsonism. Arch. Neurol. 1967; 17: 124-136.
2. McEvoy JP. The clinical use of anticholinergic drugs as treatment for for extrapyramidal side effects of neuroleptic drugs. J. Clin. Psychopharmacol. 1983; 3: 288-301.
3. Brimblecombe RW. Review of tremorogenic agents. In: Walter PG, editor. Cholinergic Mechanisms, New York: Raven Press, 1975. Pp 405-410.
4. Aquilonius SM. Cholinergic mechanisms in the CNS related to Parkinson's disease. In: Parkinson's Disease - Current Progress, Problems and Management. Elsevier: North Holland, 1980. pp. 17-27.
5. Ott BR, Lannon MC. (1992) Exacerbation of Parkinsonism by tacrine. Clin. Neuropharm. 1992; 15: 322-325.
6. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A. Tremulous jaw movements in rats: A model of parkinsonian tremor. Prog. Neurobiol. 1998; 56: 591-611.
7. Rupniak NMJ, Jenner P, Marsden CD. Cholinergic modulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacol. 1983; 79: 226-230.
8. Salamone JD, Lalies MD, Channell SL, Iversen SD. Behavioral and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacol. 1986; 88: 467-471.
9. Salamone JD, Johnson CJ, McCullough LD, Steinpreis RE. Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacol. 1990; 102: 529-534.
10. Mayorga AJ, Carriero DL, Cousins MS, Gianutsos G, Salamone JD. Tremulous jaw movements produced by acute tacrine administration: Possible relation to parkinsonian side effects. Pharmacol. Biochem. Behav. 1997; 56: 273-279.
11. Finn M, Jassen A, Baskin P, Salamone JD. Tremulous characteristics of the jaw movements. Pharmacol. Biochem. Behav. 1997; 57: 243-249.
12. Cousins MS, Finn M, Trevitt J, Carriero DL, Conlan A, Salamone JD. The role of ventrolateral striatal acetylcholine in the production of tacrine-induced jaw movements. Pharmacol. Biochem. Behav. 1999; 62: 439-447.
13. Carlson BB, Trevitt JT, Salamone JD. Effects of H1 antagonists on cholinomimetic-induced tremulous jaw movements: Studies of diphenhydramine, doxepin and mepyramine. Pharmacol. Biochem.Behav. 2000; 65: 683-689.
14. Cousins MS, Carriero DL, Salamone JD. Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: Effects of antiparkinsonian drugs. Eur. J. Pharmacol. 1997; 322: 137-145.
15. Stewart BR, Jenner P, Marsden CD. The pharmacological characterization of pilocarpine-induced chewing in the rat. Psychopharmacol. 1988; 97: 228-234.
16. Lentini E. Effects of Pergolide in a Rat Model of Parkinsonian Tremor. Honors Thesis, University of Connecticut, 2000.
17. Rios C. Ropinirole Reduces Tremor in a Rat Model of Parkinson's Disease and It's Actions are not Reversed by D1 or D2 Antagonists. Honors Thesis, University of Connecticut, 2000
18. Mayorga AJ, Trevitt JT, Conlan A, Gianutsos G, Salamone JD. Striatal and nigral mechanisms involved in the antiparkinsonian effects of SKF 82958 (APB): Studies in an animal model of tremor. Psychopharmacol. 1999; 56: 273-279.
19. Salamone JD. Centrally acting antagonists of muscarinic M4 receptors. Emerging Therapeutic Targets. 1997; 1:93-95.
20. 2 through a correlation of in vivo microdialysis and in vitro receptor binding. J. PharmaCol. Exp. Ther. 1995; 273: 273-279.
21. 4 muscarinic receptor proteins in the rat striatum: Light and electron microscopic immunocytochemistry using subtype-specific antibodies. J. Neurosci. 1994;14: 3351-3363.
22. Mayorga AJ, Cousins MS, Conlan A, Gianutsos G, Salamone, JD. Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. Eur. J. Pharmacol. 1999; 364: 7-11.
23. Lazareno S, Buckley NJ, Roberts F. Characterization of muscarinic m4 binding sites in rabbit lung, chicken heart and NG108-15 cells. Mol. Pharm. 1994; 38: 805.
24. Mayorga AJ, Gianutsos G, Salamone JD. Effects of striatal injections of 8-bromo-cyclic-AMP on pilocarpine-induced jaw movements in rats. Brain Res. 1999; 180-184.
25. Gomeza J, Zhang L, Kostenis E, Felder C, Bymaster F, Brodkin J, Shannon H, Xia B, Deng C, Wess J. Enhancement of D1 dopamine receptor-mediated locomotor stimulation in M4 muscarinic acetylcholine receptor knockout mice. Proc. Natl. Acad. Sci. 1999; 10483-10488.